A growing number of Americans are willing to have a coronavirus inoculation according to the latest IBD / TIPP poll, and it turns out to be a boon for vaccine stocks Pfizer (PFE).
In January, 60% of Americans surveyed said they would likely get a Covid-19 vaccine when one became available to them. That is only 52% in the IBD / TIPP poll in December. More than a third, 35%, say they do not want to. The rest is uncertain.
Meanwhile, Pfizer is the most reliable vaccine strain, according to the IBD / TIPP Poll. More than half of Americans surveyed, 53%, say they trust Pfizer to deliver a safe coronavirus vaccine. Pfizer shares fell 0.3% to 36.75 on Thursday.
That puts Pfizer far above its peers in the group Operation Warp Speed. Less than half of the respondents expressed confidence Johnson & Johnson (JNJ), Modern (MRNA), AstraZeneca (AZN), GlaxoSmithKline (GSK), Novavax (NVAX) and Sanofi (SNY). Only 12% of respondents trust all of these vaccines.
Behind Pfizer, 48% and 45%, respectively, trust Johnson & Johnson and Moderna.
Vaccine stocks and how to induce herd immunity
Most over half of Americans, 56%, are convinced that the first Covid-19 vaccines will be safe and effective, according to the recent IBD / TIPP poll. But more than a third, 35%, are not confident.
This means that the efforts of pharmaceutical companies may not be sufficient to prevent herd immunity. The issue of herd immunity is key as the world shatters the numbers of how many people need a Covid-19 jab to starve the virus.
The most confident group are people aged 65 and over. In this group, 70% of the population expect the first Covid-19 vaccines to be safe and effective. The least confident group were people aged 18-24. About half, 49%, are unsure of the effectiveness or safety of vaccine stock products.
Americans are grossly divided in their views on the government’s distribution of vaccines. One third say the government is doing a bad job, while 31% say the government is doing a good job. More than a quarter, 28%, say the government is doing an average job and 8% are insecure.
10 million have received shots
According to the U.S. Centers for Disease Control and Prevention, more than 10 million people had received their first coronavirus vaccine as of early Wednesday. North of 29 million doses had been distributed.
Moncef Slaoui, head of Operation Warp Speed, said Wednesday during the annual JP Morgan Healthcare Conference that less effective vaccines can help induce herd immunity if 80% -90% of the population is immunized.
Coronavirus shot from vaccine stock Pfizer with partner BioNTech (BNTX) and Moderna are 95% and 94.1% effective against Covid-19. Meanwhile, the Food and Drug Administration requires only 50% efficiency for an injection to get permission for emergency use.
Even that “would save millions of lives,” Slaoui said – provided enough people are vaccinated. Slaoui resigned his position on Wednesday, according to several reports. He will remain in office for 30 days after President-elect Joe Biden takes office.
During the JP Morgan discussion on Wednesday, Pfizer Biopharmaceuticals President Angela Hwang said her company has shipped approx. 30 million doses of its coronavirus vaccine. The vaccine strain sees Covid-19 shots as being “a viable business,” she said.
J&J is expected to follow soon
Johnson & Johnson has not yet produced Phase 3 test results for its coronavirus vaccine. Also on Wednesday, reports suggested that J&J is two months behind in production. The company said in an email statement that it is too early to discuss its delivery.
“The pandemic shows no signs of abating, and we are all eager for more tools to stop it,” J&J said in a statement sent to Investor’s Business Daily. “At the same time, it is too early to elaborate on the delivery of our vaccine candidate, as we do not yet have Phase 3 data, nor have we submitted or received an emergency use permit.”
Currently, Pfizer and Moderna are the only vaccine stocks licensed in the United States. J&J could have test results as soon as late January or early February, according to Reuters. It would help its coronavirus vaccine roll out in March.
AstraZeneca is licensed in the United Kingdom
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
The J&J stock is declining upon reporting that its covide vaccine is 2 months behind schedule
Pfizer is switching to the 200-day line on earnings prospects that delayed some impressions
Stock market today: Track market trends and the best stocks to see
Find today’s best growth stocks to see with IBD 50
View IBD stock lists and get passed / unapproved reviews for all your shares with IBD Digital